Select Your Location:

A First-in-Human, Phase 1 Study of BGB-15025 (Hematopoietic Progenitor Kinase 1 [HPK1] inhibitor) as Monotherapy and in Combination With Tislelizumab (anti-PD-1 Antibody) in Patients With Advanced Solid Tumors